Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Chung

Podiatrist, Foot & Ankle Surgery Lake Ridge, VA Doctor of Podiatric Medicine

NPI 1528598281 CMS profile 4143124

1721 Financial Loop, Lake Ridge, VA 22192

Open in the dashboard

General payments

$22,879

142 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Chung of Lake Ridge, VA is reported in the CMS Open Payments database as having received $22,879 across 142 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,437 25
2024 General $3,445 16
2023 General $940 15
2022 General $813 27
2021 General $1,471 41
2020 General $484 12
2019 General $290 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Chung
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to James Chung were reported at $15,437. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year James Chung Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $290 $389 $118–$1,406 $163
2020 $484 $191 $62–$691 $114
2021 $1,471 $329 $104–$1,341 $132
2022 $813 $419 $125–$1,611 $149
2023 $940 $377 $128–$1,164 $160
2024 $3,445 $394 $134–$1,168 $164
2025 $15,437 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Treace Medical Concepts, Inc. $13,917 14 payments
  2. Novastep Inc. $1,546 4 payments
  3. Ortho Solutions Inc $1,405 2 payments
  4. Exactech, Inc. $1,308 5 payments
  5. Zimmer Biomet Holdings, Inc. $1,089 13 payments
  6. Stryker Corporation $1,017 16 payments
  7. International Life Sciences $349 2 payments
  8. Paratek Pharmaceuticals, Inc. $315 18 payments
  9. Smith+Nephew, Inc. $287 9 payments
  10. Horizon Therapeutics plc $229 14 payments
  11. Other $1,417 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $13,420 5 payments
  2. Food and Beverage $4,570 117 payments
  3. Travel and Lodging $3,453 16 payments
  4. Honoraria $1,400 1 payment
  5. Education $37 3 payments
Products named General payments · program years 2019–2025
  1. LAPIPLASTY SYSTEM 1 $13,407 9 payments
  2. NEXIS $1,546 4 payments
  3. Trabecular Metal (TM) Ankle $772 9 payments
  4. TMC NANOPLASTY SYSTEM $496 4 payments
  5. VANTAGE $405 2 payments
  6. EASYFUSE $331 2 payments
  7. NUZYRA $315 18 payments
  8. AUGMENT INJECTABLE $229 2 payments
  9. ADHERUS AUTOSPRAY DURAL SEALANT $190 7 payments
  10. AXS INFINITY LS $171 1 payment
  11. Other $4,052 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

356

Median for Podiatry: 160

Drug cost

$17,377

Median for Podiatry: $2,368

Branded share of claims

7.6%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jublia Efinaconazole Brand 16 $14,052
Nystatin Generic 53 $877
Ketoconazole Generic 24 $506
Gentamicin Sulfate Generic 19 $440
Doxycycline Monohydrate Generic 20 $246
Gabapentin Generic 40 $229
Mupirocin Generic 23 $195
Diclofenac Sodium Generic 16 $181
Terbinafine Hcl Generic 20 $128
Ibuprofen Generic 28 $113

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$254,489

Of which drugs: $121,389

Medicare patients

435

Average age 74

Services billed

2,993

253 women, 182 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 51%
Diabetes 45%
Ischemic heart disease 32%
Chronic kidney disease 24%
Atrial fibrillation 19%
Heart failure 17%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 74 100 $69
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 61 139 $12

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

142 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record